Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07617727 | A Phase I Study of JSKN021 in Advanced Solid Tumors | recruiting | Phase 1 | 199 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07744243 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07763639 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07778862 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07785193 | A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 29 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787208 | A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 80 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787520 | A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors | not yet recruiting | Phase 1 | 150 | Laekna LimitedINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05718219 | Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors | terminated | Phase 1 | 49 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06818812 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | active not recruiting | Phase 1 | 30 | Incyte CorporationINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | recruiting | Phase 1 / Phase 2 | 107 | STORM Therapeutics LTDINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07193511 | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | recruiting | Phase 1 / Phase 2 | 355 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07681882 | First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 45 | Daiichi SankyoINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784777 | NK Cell Injection for Advanced Solid Tumors | not yet recruiting | Phase 1 | 9 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 25, 2026 | clinicaltrials |
| NCT02992210 | Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05687136 | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | recruiting | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05901285 | Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 48 | Vaxiion TherapeuticsINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06417554 | A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | suspended | Phase 1 / Phase 2 | 81 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06803680 | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 90 | BeOne MedicinesINDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT07676903 | A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors | recruiting | Phase 1 | 170 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | active not recruiting | Phase 1 / Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05765851 | A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 108 | Daiichi SankyoINDUSTRY | 5 | Aug 21, 2026 | clinicaltrials |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | recruiting | Phase 1 / Phase 2 | 166 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07779798 | A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.(TelOscope) | not yet recruiting | Phase 1 | 120 | Crossbow Therapeutics, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04572451 | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma | active not recruiting | Phase 1 | 50 | Yana NajjarOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05580770 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 23 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06154291 | FIH XON7 in Advanced/Metastatic Solid Tumors(FIPO23) | recruiting | Phase 1 / Phase 2 | 255 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06741644 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 800 | CStone PharmaceuticalsINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT07775703 | HS-20117-2 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00740805 | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03454035 | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | recruiting | Phase 1 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | recruiting | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04725474 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)(GDFATHER) | active not recruiting | Phase 1 / Phase 2 | 199 | CatalYm GmbHINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT05155332 | A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | suspended | Phase 1 | 190 | Boehringer IngelheimINDUSTRY | 10 | Aug 19, 2026 | clinicaltrials |
| NCT06144671 | Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Grit BiotechnologyINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07128303 | Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors | recruiting | Phase 1 | 476 | Gilead SciencesINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT07774611 | An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 180 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04928508 | Advanced or Recurrent Solid Tumors Treated With SHetA2(Okgyn1) | active not recruiting | Phase 1 | 50 | University of OklahomaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00045201 | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT00750841 | Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours | active not recruiting | Phase 1 | 64 | AstraZenecaINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2026source: clinicaltrials